SEP
UTHR icon

Signature Equity Partners’s United Therapeutics UTHR Stock Holding History

Signature Equity Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.9K Sell
118
-29
-20% -$16.3K 0.03% 371
2026
Q1 		$87.2K Sell
147
-6
-4% -$2.99K 0.05% 306
2025
Q4 		$74.5K Buy
+153
New +$71.3K 0.04% 328

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Signature Equity Partners's UTHR Position: Q2 2026 in Review

Signature Equity Partners reduced its United Therapeutics (UTHR) stake by 20% in Q2 2026, selling an estimated $16.3K and leaving 118 shares worth $63.9K. The position accounts for 0.03% of the portfolio, ranked #371.

Signature Equity Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $87.2K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Signature Equity Partners held 118 shares of United Therapeutics worth $63.9K as of Q2 2026.
  • Signature Equity Partners sold 29 United Therapeutics shares in Q2 2026, an estimated $16.3K.
  • United Therapeutics made up 0.03% of Signature Equity Partners's portfolio in Q2 2026, its #371 holding.
  • Signature Equity Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's United Therapeutics position peaked at $87.2K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.